Tag
This study reveals that dual BAFF-APRIL blockade with telitacicept distinctly remodels pathogenic autoantibodies in antiphospholipid syndrome, showing differential effects across immunoglobulin isotypes and identifying marrow plasma-cell cl
In 1,067 persistently antiphospholipid antibody–positive patients followed for 4,727 person‑years, prior thrombosis and coexistent hematologic disease each conferred ~2‑fold increased risk for new thrombosis; microvascular disease and obesi
EULAR’s new antiphospholipid syndrome disease activity score (EAPSDAS) provides the first standardized, validated tool to measure APS activity across thrombotic, microvascular and obstetric manifestations — a major advance for clinical care
A multinational cross-sectional study of 1003 people with antiphospholipid syndrome (APS) found high prevalence of hypertension, hyperlipidaemia, obesity and smoking, with suboptimal attainment of guideline targets — particularly among thos
The IMPACT trial demonstrates that adding certolizumab pegol to standard therapy reduces placenta-mediated adverse pregnancy outcomes in women with antiphospholipid syndrome and lupus anticoagulant, with favorable safety and neonatal outcom
